We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

We recently compiled a list of the 7 Blue Chip Stocks with Low PE Ratios. In this article, we are going to take a look at ...

German science and technology group Merck is open to more acquisitions for its Life Science business after announcing in May ...

Clesrovimab (MK-1654), an Investigational RSV Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and ...

Summit Therapeutics has a pipeline candidate that could be more effective than Merck's Keytruda. It's a good start ...

Merck's recent decline is due to reduced profit guidance and FDA decisions, but shares are at a support level. Read why I ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark Equity and Income Fund” third quarter 2024 investor letter ...

On Oct. 1 and 2, the American Chemical Society held its 21st annual Pharma Leaders Conference, hosted this year at the Merck & Co. campus in Rahway, New Jersey. Leaders in medicinal chemistry from ...

Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.

The latest trading day saw Merck (MRK) settling at $111.53, representing a +1.68% change from its previous close.

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $100.0 to $120.0 for Merck & Co over the last 3 months.